ReviewInternational journal of molecular sciences2021
Recent Advances in Gene Therapy for Cardiac Tissue Regeneration.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- FSTL-1 as a Novel Cardiokine of Cardiac Angiogenesis: A Systematic Review.Vascular health and risk management · 2025Pooled it
- Review
- Advances in Diagnosis and Treatment of Acute and Chronic Heart Failure: A Comprehensive Review.Journal of clinical medicine · 2026Review
- Therapeutic Targets for Myocardial Fibrosis: A Comprehensive Review of Current and Emerging Approaches.Cardiovascular & hematological disorders drug targets · 2026Review
- Regional and cell specific bioactivity of injectable extracellular matrix biomaterials in myocardial infarction.Nature communications · 2025Article
- Flow cytometry of the myocardium: An end-to-end analysis of adult cardiomyocytes isolated from pig and mouse hearts.Journal of molecular and cellular cardiology · 2025Article
- Age reprogramming: Innovations and ethical considerations for prolonged longevity (Review).Biomedical reports · 2025Review
- Clinical course of respiratory tuberculosis relapses in the Kazakh population depending on HLA-DRB1 gene alleles.Virusdisease · 2024Article
- Heart immunoengineering by lentiviral vector-mediated genetic modification during normothermicFrontiers in immunology · 2024Article
- Progress and prospects of gene therapy in ophthalmology from 2000 to 2022: A bibliometric analysis.Heliyon · 2023Article
- Review
- Gene Therapy for Cardiomyocyte Renewal: Cell Cycle, a Potential Therapeutic Target.Molecular diagnosis & therapy · 2023Article
- A Review of Genes Involved in Wound Healing.Medical journal of the Islamic Republic of Iran · 2023Review
- Novel Therapies for the Treatment of Cardiac Fibrosis Following Myocardial Infarction.Biomedicines · 2022Review
- The Angiogenic Balance and Its Implications in Cancer and Cardiovascular Diseases: An Overview.Medicina (Kaunas, Lithuania) · 2022Review
- Transcriptional Regulation of Cardiac Development and Disease.International journal of molecular sciences · 2022Article
- Ionizable Lipid Nanoparticle-Mediated Delivery of Plasmid DNA in Cardiomyocytes.International journal of nanomedicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Cardiovascular diseases (CVDs) are responsible for enormous socio-economic impact and the highest mortality globally. The standard of care for CVDs, which includes medications and surgical interventions, in most cases, can delay but not prevent the progression of disease. Gene therapy has been considered as a potential therapy to improve the outcomes of CVDs as it targets the molecular mechanisms implicated in heart failure. Cardiac reprogramming, therapeutic angiogenesis using growth factors, antioxidant, and anti-apoptotic therapies are the modalities of cardiac gene therapy that have led to promising results in preclinical studies. Despite the benefits observed in animal studies, the attempts to translate them to humans have been inconsistent so far. Low concentration of the gene product at the target site, incomplete understanding of the molecular pathways of the disease, selected gene delivery method, difference between animal models and humans among others are probable causes of the inconsistent results in clinics. In this review, we discuss the most recent applications of the aforementioned gene therapy strategies to improve cardiac tissue regeneration in preclinical and clinical studies as well as the challenges associated with them. In addition, we consider ongoing gene therapy clinical trials focused on cardiac regeneration in CVDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.